[HTML][HTML] Prospective study of acute HIV-1 infection in adults in East Africa and Thailand
ML Robb, LA Eller, H Kibuuka, K Rono… - … England Journal of …, 2016 - Mass Medical Soc
Background Acute human immunodeficiency virus type 1 (HIV-1) infection is a major contributor
to transmission of HIV-1. An understanding of acute HIV-1 infection may be important in …
to transmission of HIV-1. An understanding of acute HIV-1 infection may be important in …
[HTML][HTML] Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
…, P Thongcharoen, ML Robb… - … England Journal of …, 2009 - Mass Medical Soc
Background The development of a safe and effective vaccine against the human immunodeficiency
virus type 1 (HIV-1) is critical to pandemic control. Methods In a community-based, …
virus type 1 (HIV-1) is critical to pandemic control. Methods In a community-based, …
Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19
Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …
Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine
…, I Hirsch, S Sproule, ML Robb, L Corey… - … England Journal of …, 2021 - Mass Medical Soc
Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…
Immune-correlates analysis of an HIV-1 vaccine efficacy trial
…, E Billings, N Karasavvas, ML Robb… - … England Journal of …, 2012 - Mass Medical Soc
Background In the RV144 trial, the estimated efficacy of a vaccine regimen against human
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case–control analysis to …
Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6 PD by passive transfer of neutralizing antibodies
…, CV Sapan, SS Frankel, Y Lu, ML Robb… - Journal of …, 1999 - Am Soc Microbiol
The role of antibody in protection against human immunodeficiency virus (HIV-1) has been
difficult to study in animal models because most primary HIV-1 strains do not infect …
difficult to study in animal models because most primary HIV-1 strains do not infect …
Human skin Langerhans cells are targets of dengue virus infection
…, HK Wong, A Blauvelt, GS Murphy, ML Robb… - Nature medicine, 2000 - nature.com
Dengue virus (DV), an arthropod-borne flavivirus, causes a febrile illness for which there is
no antiviral treatment and no vaccine 1, 2. Macrophages are important in dengue …
no antiviral treatment and no vaccine 1, 2. Macrophages are important in dengue …
Final analysis of efficacy and safety of single-dose Ad26. COV2. S
…, J Custers, G Scheper, ML Robb… - … England Journal of …, 2022 - Mass Medical Soc
Background The Ad26.COV2.S vaccine was highly effective against severe–critical coronavirus
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …
disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy …
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
…, B Li, J Hesselgesser, R Geleziunas, ML Robb… - Nature, 2014 - nature.com
The viral reservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1)
eradication strategies 1 , 2 , 3 , 4 , 5 . However, it remains unclear when and where …
eradication strategies 1 , 2 , 3 , 4 , 5 . However, it remains unclear when and where …
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys
…, JC Sadoff, EA Billings, M Rao, ML Robb… - Nature, 2012 - nature.com
Preclinical studies of human immunodeficiency virus type 1 (HIV-1) vaccine candidates
have typically shown post-infection virological control, but protection against acquisition of …
have typically shown post-infection virological control, but protection against acquisition of …